Diasorin S.p.a. · MIL:DIA
Diasorin — STAR Conference Milan 2010
22 slides from Diasorin's conference presentation, March 2010
Slide 1: Diasorin STAR Conference Milan 2010
Diasorin STAR Conference Milan 2010
Slide 2: Disclaimer
Disclaimer Save where otherwise indicated, the Company is the source of the content of this Presentation. Care has been taken to ensure that the facts stated in this Presentation are accurate, and that the opinions expressed are fair and reasonable. However, no representation or warranty, express or
Slide 3: In vitro diagnostic process
In vitro diagnostic process 1 2 3 Physician takes Sends the Automatic sample blood sample sample to a lab testing 5 4 Results Highly specific used to help test results sent determine diagnosis back to physician STAR Conference - Milan Mar. 2010 2
Slide 4: Global IVD market
Global IVD market Global market size 2009 (€30bn) Others Immuno- 9% assay 22% SMBG 21% Clinical Microbiol. Chemistry 6% 20% POC 6% Molecular Hematology Diagnostics 6% 8% STAR Conference - Milan Mar. 2010 3
Slide 5: Global footprint
Global footprint Direct presence Distributors Manufacturing facilities and R&D centres of excellence STAR Conference - Milan Mar. 2010 4
Slide 6: LIAISON platform (CLIA technology)
LIAISON platform (CLIA technology) ● State-of-the-art fully automated immunoassay instrument ● 180 tests per hour ● Provides basis for competitive product offering ● high quality & accuracy of test results ● easy to use ● Closed system ● Highest margins of DiaSorin’s technology platforms STAR Confer
Slide 7: An innovation strategy…
An innovation strategy… …able to build one of the broadest and specialist test menu available on the market on LIAISON, during the last ten years: 85 total LIAISON assays CE marked, 36 are specialty assays of which 23 LIAISON also available in US. (up to 23/02/10) Total number of assays Number of sp
Slide 8: Installed base growth
Installed base growth Leadership in specialty assays is a competitive advantage in getting instruments placed LIAISON installed base 2,975 2,510 2,070 990 Source: DiaSorin Group 2004 2007 2008 2009 Instrument/consumables business model yields strong recurring revenue base STAR Conference - Milan Mar
Slide 9: Strategic Guidelines: Main Growth Drivers
Strategic Guidelines: 5 Main Growth Drivers ● Development of new assays (menu expansion), including HIV and HCV ● Development of a new proprietary testing platform (LIAISON XL) ● Development of new assay technologies, including molecular diagnostics research GROWTH (new IVD segment) ● Geographical e
Slide 10: New assays and new platform (Liaison XL)
New assays and new platform (Liaison XL) Strengthening of New Markets with New Test s available Keep exploring specialty assays Infectious Disease and only on the New Liaison XL platform markets Endocrinology panel Chlamidia Chlamidia Parvovirus Anti HBs 2.0 Trachomatis Pneumoniae Mycoplasma HIV Com
Slide 11: Vitamin D Penetration 2009
Vitamin D Penetration 2009 Low in most markets VIT D PENETRATION / 1000 INHABITANTS 120 104,2 MKT TESTS 95,8 95,6 100 88,6 DS TESTS 84,6 78,0 80 Tests / 1000 inhab 60 53,2 40 34,4 20 15,8 14,6 11,2 9,3 8,0 9,0 9,0 5,8 4,7 0,4 2,0 0,5 0 Based on EDMA data at constant ASP in EU countries, and company
Slide 12: Vitamin D: U.S.A. Market Potential to double
Vitamin D: U.S.A. Market Potential to double ● 40% (120 million) of the US population is Vitamin D deficient* or insufficient, but only ¼ is tested ● Vitamin D tests/year can double, from 30M estimated in 2009 to more than 60M in the next 5 years (19% penetration), still, less than 50% of Vitamin D
Slide 13: Vitamin D: U.S.A. Market Strategy
Vitamin D: U.S.A. Market Strategy IFU Claim Expansion: Vitamin D and Blood pressure ● 380 Million (1/3) of Europe and North America population is at risk of developing Hypertension ● Even a modest Blood Pressure lowering leads to reduction in cardiovascular mortality STAR Conference - Milan Mar. 201
Slide 14: Vitamin D: Europe Market Potential to triplicate
Vitamin D: Europe Market Potential to triplicate ● 40% (150 million) of Europeans are Vitamin D deficient or insufficient, but less than 7% are tested ● Vitamin D tests/year can triplicate, from 9.5M estimated in 2009 to 30M in the next 5 years (7.5% penetration), still, only 1/5 of Vitamin D defici
Slide 15: Vitamin D: Japan, Untouched opportunity
Vitamin D: Japan, Untouched opportunity In Japan, Calcium and Vitamin D deficiency is more prevalent than in the USA and Europe*1 • Osteoporosis: 13 million cases • Treatment given only in advanced disease • Rare use of estrogenic replacement therapy (culture) • Common use of Vitamin D derivatives a
Slide 16: Murex is Abbott arm in HIV and Hepatitis blood screening
“Murex is Abbott arm in HIV and Hepatitis blood screening testing outside Europe, US and Japan where ELISA still plays a role.” 15
Slide 17: Murex Assets acquired by DiaSorin
Murex Assets acquired by DiaSorin ● Two manufacturing sites, Dartford in UK and Kyalami in SA, employing less than 250 people. ● The use of MUREX Brand. ● All the raw material currently used by Abbott to make the EIA products for HIV, HCV and HBV. ● All relevant IP (either transferred or licensed) n
Slide 18: Murex 2009 sales by Geographical Area
Murex 2009 sales by Geographical Area Europe APAC 25,9% 27,5% South America 46,6% STAR Conference - Milan Mar. 2010 17
Slide 19: Murex is key to DiaSorin's success in HIV and HEP
Murex is key to DiaSorin’s success in HIV and HEP 1. Current know-how and reputation of Murex in the field of HCV and HIV will allow DiaSorin to leverage on a strong brand. 2. Integration of current sales of Murex in South America and Asia/Pacific will allow us to increase our critical mass in those
Slide 20: Murex business – Key financials
Murex business – Key financials Murex turnover ACT 09 (Dec-Nov): USD 66.7 mln (including instrument sales): ● Murex turnover EST 10 (Dec- Nov): USD 60-65 mln ● Expected consolidated sales FY 10: USD ~ 30 mln (€ ~ 21 mln) Murex will be accretive as of year 1. We expect: ● EbITDA margin between 15-19%
Slide 21: Successful track record
Successful track record millions € FY 2009E FY 2008 D Net Revenues 304.1 244.6 +24.3% Ebit 105.4 70.8 +49% Margin 34.7% 28.9% Net Result 69.8 37.5 +86.3% Ebitda 122.6 85.6 +43.2% Margin 40.3% 35.0% 45% 30% 40% 40.3% 25% 35.0% 24.3% 20.9% 35% 31.6% 34.7% 29.2% 20% 30% 14.8% 15% 25% 28.9% 24.7% 10% 20
Slide 22: Contact details: Laura Villa
Contact details: Laura Villa Investor Relations Manager tel. +39 0161.487964 mob. +39 348 15 11 542 laura.villa@diasorin.it